These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 31298062)

  • 1. Upfront radiation is essential for high-risk early-stage extranodal NK/T-cell lymphoma, nasal type: comparison of two sequential treatment modalities combining radiotherapy and GDP (gemcitabine, dexamethasone, and cisplatin) in the modern era.
    Qi F; Chen B; Wang J; Lin X; Qi S; Yang J; Zhou S; Wang S; Gui L; Fang H; Liu P; Song Y; Yang S; Li Y; Dong M
    Leuk Lymphoma; 2019 Nov; 60(11):2679-2688. PubMed ID: 31298062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term outcomes of upfront concurrent chemoradiotherapy followed by P-GDP regimen in newly diagnosed early stage extranodal nasal-type NK/T cell lymphoma: A prospective single-center phase II study.
    Zhu F; Liu T; Pan H; Xiao Y; Li Q; Liu X; Chen W; Wu G; Zhang L
    Medicine (Baltimore); 2020 Aug; 99(33):e21705. PubMed ID: 32872045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined use of DDGP and IMRT has a good effect on extranodal natural killer/T-cell lymphoma, nasal type.
    Zheng Y; Yang C; Liang T; Yang D; Liu Z
    Hematol Oncol; 2020 Feb; 38(1):103-105. PubMed ID: 31102421
    [No Abstract]   [Full Text] [Related]  

  • 4. The DDGP (cisplatin, dexamethasone, gemcitabine, and pegaspargase) regimen for treatment of extranodal natural killer (NK)/T-cell lymphoma, nasal type.
    Zhang L; Li S; Jia S; Nan F; Li Z; Cao J; Fan S; Zhang C; Su L; Wang J; Xue H; Zhang M
    Oncotarget; 2016 Sep; 7(36):58396-58404. PubMed ID: 27517317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined gemcitabine, cisplatin, dexamethasone, methotrexate, and pegaspargase (GDP-ML) for patients with newly diagnosed extranodal natural killer/T cell lymphoma, nasal type: a single arm, single center, prospective phase 2 study.
    Wei C; Cao X; Zhang W; Zhang Y; Wang W; Zhang L; Yang C; Feng J; Cai H; Chen M; Mao Y; Zhou D
    Ann Hematol; 2020 Dec; 99(12):2801-2809. PubMed ID: 32399707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensity-modulated radiation therapy followed by GDP chemotherapy for newly diagnosed stage I/II extranodal natural killer/T cell lymphoma, nasal type.
    Huang Y; Yang J; Liu P; Zhou S; Gui L; He X; Qin Y; Zhang C; Yang S; Xing P; Sun Y; Shi Y
    Ann Hematol; 2017 Sep; 96(9):1477-1483. PubMed ID: 28695246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of primary tumor invasion on treatment and survival in extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: a multicenter study from the China Lymphoma Collaborative Group (CLCG).
    Qi SN; Xu LM; Yuan ZY; Wu T; Zhu SY; Shi M; Su H; Wang Y; He X; Zhang LL; Wu G; Qu BL; Qian LT; Hou XR; Zhang FQ; Zhang YJ; Zhu Y; Cao JZ; Lan SM; Wu JX; Yang Y; Li YX
    Leuk Lymphoma; 2019 Nov; 60(11):2669-2678. PubMed ID: 31060406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concurrent Chemoradiation Therapy Followed by Consolidation Chemotherapy for Localized Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type.
    Oh D; Ahn YC; Kim SJ; Kim WS; Ko YH
    Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):677-83. PubMed ID: 26461010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine, dexamethasone, and cisplatin (GDP) chemotherapy with sandwiched radiotherapy in the treatment of newly diagnosed stage IE/IIE extranodal natural killer/T-cell lymphoma, nasal type.
    Tian S; Li R; Wang T; Wang S; Tao R; Hu X; Ding H
    Cancer Med; 2019 Jul; 8(7):3349-3358. PubMed ID: 31050212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiotherapy vs sequential pegaspargase, gemcitabine, cisplatin and dexamethasone and radiotherapy in newly diagnosed early natural killer/T-cell lymphoma: A randomized, controlled, open-label, multicenter study.
    Zhang L; Wang Y; Li X; Li L; Wang X; Sun Z; Wu J; Fu X; Zhang X; Yu H; Wang G; Chang Y; Yan J; Zhou Z; Wu X; Nan F; Li W; Zhang M
    Int J Cancer; 2021 Mar; 148(6):1470-1477. PubMed ID: 33034052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 2 Study of First-line Intensity Modulated Radiation Therapy Followed by Gemcitabine, Dexamethasone, and Cisplatin for High-Risk, Early Stage Extranodal Nasal-Type NK/T-Cell Lymphoma: The GREEN Study.
    Qi F; Wang WH; He XH; Chen B; Gui L; Fang H; Liu P; Wang SL; Yang JL; Song YW; Yang S; Qi SN; Zhou SY; Li YX; Dong M
    Int J Radiat Oncol Biol Phys; 2018 Sep; 102(1):61-70. PubMed ID: 30102205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX) chemotherapy combined with radiotherapy in newly diagnosed, stage IE to IIE, nasal-type, extranodal natural killer/T-cell lymphoma.
    Wei W; Wu P; Li L; Zhang ZH
    Hematology; 2017 Jul; 22(6):320-329. PubMed ID: 27917702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment and Prognosis of Newly Diagnosed Advanced-Stage Extranodal Natural Killer/T-Cell Lymphoma: A Single-Center Real-World Study across Two Decades.
    Wei YC; Qi F; Chen B; Zhang CG; Fang H; Zhang D; Qi SN; Chai Y; Li YX; Dong M
    Chemotherapy; 2024; 69(2):108-121. PubMed ID: 37984344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concurrent IMRT and weekly cisplatin followed by GDP chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell lymphoma.
    Ke QH; Zhou SQ; Du W; Liang G; Lei Y; Luo F
    Blood Cancer J; 2014 Dec; 4(12):e267. PubMed ID: 25501024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008).
    Yoon DH; Kim SJ; Jeong SH; Shin DY; Bae SH; Hong J; Park SK; Yhim HY; Yang DH; Lee H; Kang HJ; Lee MH; Eom HS; Kwak JY; Lee JH; Suh C; Kim WS
    Oncotarget; 2016 Dec; 7(51):85584-85591. PubMed ID: 27542213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiotherapy is essential after complete response to asparaginase-containing chemotherapy in early-stage extranodal nasal-type NK/T-cell lymphoma: A multicenter study from the China Lymphoma Collaborative Group (CLCG).
    Deng XW; Wu JX; Wu T; Zhu SY; Shi M; Su H; Wang Y; He X; Xu LM; Yuan ZY; Zhang LL; Wu G; Qu BL; Qian LT; Hou XR; Zhang FQ; Zhang YJ; Zhu Y; Cao JZ; Lan SM; Dong M; Qi SN; Yang Y; Li YX
    Radiother Oncol; 2018 Oct; 129(1):3-9. PubMed ID: 29739712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiotherapy and PGEMOX/GELOX regimen improved prognosis in elderly patients with early-stage extranodal NK/T-cell lymphoma.
    Bi XW; Xia Y; Zhang WW; Sun P; Liu PP; Wang Y; Huang JJ; Jiang WQ; Li ZM
    Ann Hematol; 2015 Sep; 94(9):1525-33. PubMed ID: 25957850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk-dependent curability of radiotherapy for elderly patients with early-stage extranodal nasal-type NK/T-cell lymphoma: A multicenter study from the China Lymphoma Collaborative Group (CLCG).
    Chen B; Zhu SY; Shi M; Su H; Wang Y; He X; Xu LM; Yuan ZY; Zhang LL; Wu G; Qu BL; Qian LT; Hou XR; Zhang FQ; Zhang YJ; Zhu Y; Cao JZ; Lan SM; Wu JX; Wu T; Qi SN; Yang Y; Liu X; Li YX
    Cancer Med; 2018 Dec; 7(12):5952-5961. PubMed ID: 30358175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type.
    Yamaguchi M; Suzuki R; Oguchi M
    Blood; 2018 Jun; 131(23):2528-2540. PubMed ID: 29602763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk-based, response-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: A China Lymphoma Collaborative Group study.
    Qi SN; Yang Y; Zhang YJ; Huang HQ; Wang Y; He X; Zhang LL; Wu G; Qu BL; Qian LT; Hou XR; Zhang FQ; Qiao XY; Wang H; Li GF; Zhu Y; Cao JZ; Wu JX; Wu T; Zhu SY; Shi M; Xu LM; Yuan ZY; Su H; Song YQ; Zhu J; Hu C; Li YX
    Am J Hematol; 2020 Sep; 95(9):1047-1056. PubMed ID: 32449800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.